

**19<sup>th</sup> June 2008**

**REGEN THERAPEUTICS PLC**  
(“ReGen” or the “Company”; Ticker: (RGT))

**TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES**

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

**ReGen Therapeutics Plc**

2. Reason for the notification:

**An acquisition or disposal of voting rights**

3. Full name of person(s) subject to the notification obligation (iii):

**Andrew Clement Wilson**

4. Full name of shareholder(s) (if difference from 3):

**As above**

5. Date of the transaction and date on which the threshold is crossed or reached (v):

**18 June 2008**

6. Date on which issued notified:

**19 June 2008**

7. Threshold(s) that is/are crossed or reached:

**13%**

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code	<b>GB00B28XMY25</b>
Situation Previous to the triggering transaction (vi) –	
Number of Shares	<b>1,477,000</b>
Number of Voting Rights (viii)	<b>1,477,000</b>
Resulting situation after the triggering transaction (viii) –	
Number of Shares	<b>1,495,000</b>
Number of Voting Rights – Direct (x)	<b>1,495,000</b>
Number of Voting Rights – Indirect (xi)	<b>N/A</b>
% of voting rights – Direct	<b>13.02%</b>
% of voting rights – Indirect	<b>N/A</b>

## B: Financial Instruments

### Resulting situation after the triggering transaction (xii)

Type of financial instrument	N/A
Expiration date (xiii)	N/A
Exercise/Conversion Period/Date (xiv)	N/A
Number of voting rights that may be acquired if the instrument is exercised/converted	N/A
% of voting rights	N/A
Total (A+B)	
Number of voting rights	<b>1,495,000</b>
% of voting rights	<b>13.02</b>

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

### **Shares are held in own name**

#### Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A
13. Additional information:	N/A
14. Contact name:	N/A
15. Contact telephone number:	N/A

### **For further information:**

Percy Lomax  
ReGen Therapeutics Plc  
Tel: +44 (0) 207 153 4920

Roland Cornish / Felicity Geidt  
Beaumont Cornish Limited  
Tel: +44(0) 207 628 3396